



Aggravation of atherosclerosis by parathyroid hormone access

Parto Nasri¹

Abstract

Parathyroid hormone (PTH), primarily known for its role in calcium and phosphate metabolism, has increasingly been implicated in the development and progression of atherosclerosis. Elevated PTH levels, whether due to primary or secondary hyperparathyroidism, are linked to a higher risk of cardiovascular disease, including both subclinical and overt atherosclerotic vascular disease. Evidence shows that, PTH impairs endothelial function by increasing the production of reactive oxygen species (ROS), particularly mitochondrial ROS, which leads to oxidative stress and impaired vascular relaxation. This dysfunction is a key early event in atherogenesis. Moreover, PTH stimulates endothelial cells to upregulate the expression of inflammatory markers such as interleukin-6 (IL-6) and the receptor for advanced glycation end products (RAGE), both of which are involved in vascular inflammation and plaque formation. These effects are mediated via protein kinase A (PKA) and protein kinase C (PKC) pathways and are nitric oxide (NO) dependent. Chronic elevation of PTH also promotes apoptosis of vascular smooth muscle cells (VSMCs), which precedes and contributes to vascular calcification as a hallmark of advanced atherosclerosis, since PTH-induced calcification is associated with endoplasmic reticulum (ER) stress in VSMCs. Additionally, chronic hypercalcemia driven by high PTH levels accelerates calcification of vessel walls and atherosclerotic plaques. Finally, Elevated PTH is associated with metabolic disturbances such as hyperlipidemia and impaired glucose tolerance, both of which exacerbate the atherosclerotic process.

Keywords: Parathyroid hormone, Atherosclerosis, Parathormone, Endothelial cell, Nitric oxide, Reactive oxygen species

Citation: Nasri P. Aggravation of atherosclerosis by parathyroid hormone access. J Ren Endocrinol. 2025;11:e25188. doi: 10.34172/jre.2025.25188.

Copyright © 2025 The Author(s); Published by Nickan Research Institute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Parathyroid hormone (PTH) contributes to the progression of atherosclerosis through several specific mechanisms affecting vascular structure and function (1). This hormone stimulates endothelial cells to increase the expression of the receptor for advanced glycation end products (RAGE) and interleukin-6 (IL-6) mRNA, which are involved in vascular inflammation and atherosclerosis development (2). This stimulation occurs by protein kinase C (PKC) and protein kinase A (PKA) pathways which depends on nitric oxide (NO) synthase activity. Elevated RAGE and IL-6 promote vascular calcification and arteriosclerosis, key processes in atherosclerosis progression (3). Elevated PTH (parathormone) levels are also associated with increased vascular stiffness and hypertension, both of which contribute to the development and worsening of atherosclerotic disease (4). Additionally, PTH, is a regulator of calcium and phosphate metabolism, which influences vascular calcification, as a hallmark of atherosclerosis, that especially notable in conditions like chronic kidney disease where secondary hyperparathyroidism is present (5). Finally, elevated PTH

is linked to hyperlipidemia and impaired glucose tolerance, metabolic disturbances that exacerbate atherosclerosis progression. Community-based cohort studies have demonstrated that higher circulating PTH levels are associated with greater atherosclerotic burden and an increased risk of clinically overt atherosclerotic disease, independent of traditional cardiovascular risk factors (6). Both primary and secondary hyperparathyroidism are linked to increased risks of endothelial dysfunction, vascular stiffness, hypertension, coronary artery disease, and peripheral arterial disease. These associations persist even after adjusting for classical risk factors for atherosclerosis (7). Elevated PTH levels in patients with cardiovascular disease, such as heart failure, are associated with worse outcomes, including higher rates of stroke and mortality (8). Epidemiological studies in community cohorts show that higher circulating PTH levels correlate with greater atherosclerotic burden assessed by whole-body magnetic resonance angiography and predict increased risk of clinically overt atherosclerotic disease independent of traditional cardiovascular risk factors (9).

Received: 13 Jan. 2025, Revised: 10 May 2025, Accepted: 25 May 2025, ePublished: 2 Jun. 2025

Department of Pathology, Isfahan University of Medical Sciences, Isfahan, Iran.

*Corresponding Author: Parto Nasri, Email: parto.nasri@gmail.com

■ Implication for health policy/practice/research/medical education

Elevated parathyroid hormone levels aggravate atherosclerosis through various mechanisms, including endothelial dysfunction, inflammation, vascular calcification, and metabolic disturbances. These effects contribute to an increased risk of cardiovascular morbidity and mortality in individuals with hyperparathyroidism or chronically elevated PTH, highlighting the importance of monitoring and managing PTH levels in at-risk populations.

Search strategy

For this review, we searched PubMed, Web of Science, EBSCO, Scopus, Google Scholar, Directory of Open Access Journals (DOAJ) and Embase, using different keywords such as parathyroid hormone, atherosclerosis, parathormone, endothelial cell, nitric oxide and reactive oxygen species.

Molecular and cellular mechanisms

Parathyroid hormone acts on vascular smooth muscle cells and endothelial cells via its receptor, which is expressed in these cell types (10). Several experimental evidence indicates that PTH may alter vascular tone and remodeling, possibly promoting hypertension and vascular stiffness as the risk factors to exacerbate the atherosclerosis (11). Although acute PTH exposure can stimulate endothelial vasodilation, chronic elevated PTH correlates with endothelial dysfunction in clinical studies, indicating more complex, possibly detrimental long-term effects on the vasculature (12). Elevated PTH is also linked to increased intracellular calcium in arterial walls, leading to vascular smooth muscle contraction and hypertrophy, contributing to arterial stiffness and plaque development (13). Furthermore, high parathormone concentration have been implicated in promoting vascular calcification, regarded as a hallmark of advanced atherosclerosis and arterial stiffness, particularly in contexts of hyperparathyroidism and kidney disease (4). Meanwhile, elevated PTH induces high bone turnover and medial arterial calcification resembling Mönckeberg's sclerosis, thus aggravating vascular pathology. Importantly, calcimimetic treatments lowering PTH levels can reduce vascular calcification in experimental models, supporting the causative role of PTH in this process (14).

Focus on endothelial cell function and structure by PTH excess

Parathormone influences endothelial cell function by inducing endothelial dysfunction through multiple interconnected molecular and cellular mechanisms involving calcium signaling, oxidative stress, metabolic alterations, and modulation of gene expression (15). PTH receptors (PTH1R), which are G protein-coupled receptors, are expressed in endothelial cells of various vascular beds including human valvular endothelial cells (VEC) and human umbilical vein endothelial cells (HUVECs)

(10). Binding of this hormone to these receptors initiates downstream signaling pathways that affect endothelial cell behavior (16). Meanwhile PTH exposure leads to a reduction in endothelial nitric oxide synthase (eNOS) expression and nitric oxide (NO) production, critical mediators of vascular homeostasis and vasodilation (17). This reduction in NO bioavailability contributes to endothelial dysfunction. Concurrently, PTH induces elevated reactive oxygen species (ROS) production and decreases antioxidant enzyme activities such as catalase, exacerbating oxidative stress in endothelial cells (18). Prior studies found that, this hormone impairs mitochondrial respiration and shifts endothelial cellular metabolism towards a glycolytic phenotype (12). If fact, following prolonged exposure, endothelial cells show decreased mitochondrial oxygen consumption and ATP production, accompanied by increased glycolysis, which is associated with vascular inflammation and dysfunction. Likewise, PTH activates mitogen-activated protein kinases (MAPKs), specifically p38MAPK and ERK1/2, in endothelial cells (19). These kinases modulate the expression of osteogenic and inflammatory molecules, including BMP-2, osteopontin, bone sialoprotein, and transcription factors Runx-2 and Sox9, contributing to a pro-calcific endothelial phenotype (20). Recent studies show, in human umbilical vein endothelial cells, PTH enhances store-operated Ca^{2+} entry (SOCE) by upregulation of the Orai1 channel (21). This calcium influx triggers activation of the calmodulin/calcineurin/nuclear factor of activated T cells (NFATC1) signaling pathway leading to NFATC1 nuclear translocation (21). NFATC1 in the nucleus promotes expression of collagen type I alpha 1 (COL1A1), a key extracellular matrix protein, which mediates increased endothelial cell migration and proliferation—a hallmark of endothelial dysfunction (22). Parathyroid hormone excess can induce endothelial-mesenchymal transition as a process where endothelial cells acquire mesenchymal characteristics contributing to calcification, at physiologically relevant concentrations, PTH does not significantly trigger this transition in valvular endothelial cells, suggesting dose-dependent effects (23). Since, PTH-induced endothelial dysfunction leads to secretion of mediators from endothelial cells that promote osteogenic differentiation of adjacent valvular interstitial cells (VIC) (24). This is characterized by increased expression of osteogenic molecules (BMP-2/4, osteocalcin, TGF- β 1) by VIC and decreased collagen I/III production, favoring valvular calcification and dysfunction (25).

Conclusion

Parathyroid hormone promotes atherosclerosis by inducing endothelial inflammation and dysfunction, increasing vascular stiffness, enhancing vascular calcification, and contributing to adverse metabolic profiles, thereby accelerating the development and

clinical manifestation of atherosclerotic vascular disease across with cardiovascular morbidity and mortality. The observed associations are independent of confounding factors such as calcium and vitamin D levels, highlighting this hormone as a potential target for interventions aimed at reducing vascular disease risk.

Conflicts of interest

The author declares that she has no competing interests.

Ethical issues

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the author.

Declaration of generative AI and AI-assisted technologies in the writing process

During the preparation of this work, the authors utilized Perplexity to refine grammar points and language style in writing. Subsequently, the authors thoroughly reviewed and edited the content as necessary, assuming full responsibility for the publication's content.

Funding/Support

None.

References

1. Brown SJ, Ruppe MD, Tabatabai LS. The Parathyroid Gland and Heart Disease. *Methodist Deakey Cardiovasc J*. 2017;13:49-54. doi: 10.14797/mdcj-13-2-49.
2. Rashid G, Bernheim J, Green J, Benchetrit S. Parathyroid hormone stimulates endothelial expression of atherosclerotic parameters through protein kinase pathways. *Am J Physiol Renal Physiol*. 2007;292:F1215-8. doi: 10.1152/ajprenal.00406.2006.
3. Ringvold HC, Khalil RA. Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders. *Adv Pharmacol*. 2017;78:203-301. doi: 10.1016/bs.apha.2016.06.002.
4. Grillo A, Barbato V, Antonello RM, Cola MF, Parati G, Salvi P, et al. Arterial Stiffness in Thyroid and Parathyroid Disease: A Review of Clinical Studies. *J Clin Med*. 2022;11. doi: 10.3390/jcm11113146.
5. Siracusa C, Carabetta N, Morano MB, Manica M, Strangio A, Sabatino J, et al. Understanding Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Therapeutic Implications. *Int J Mol Sci*. 2024;25. doi: 10.3390/ijms252313096.
6. Hagström E, Michaëlsson K, Melhus H, Hansen T, Ahlström H, Johansson L, et al. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community-based cohorts. *Arterioscler Thromb Vasc Biol*. 2014;34:1567-73. doi: 10.1161/atvbaha.113.303062.
7. Antignani PL, Jezovnik MK, Blinc A, Mikhailidis DP, Anagnostis P, Scherthaner GH, et al. Hyperparathyroidism and Peripheral Arterial Disease. *Curr Vasc Pharmacol*. 2024;22:88-94. doi: 10.2174/0115701611280905231227045826.
8. Chen G, Che L, Wen X, Lai M, Wei T, Zhu P, et al. Association of serum parathyroid hormone within normal range with the prevalence and prognosis among adults with diabetes and prediabetes: insight from NHANES 2003-2006 data. *Ther Adv Endocrinol Metab*. 2025;16:20420188251328806. doi: 10.1177/20420188251328806.
9. Hagström E, Hellman P, Larsson TE, Ingelsson E, Berglund L, Sundström J, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. *Circulation*. 2009;119:2765-71. doi: 10.1161/circulationaha.108.808733.
10. Vadana M, Cecoltan S, Ciortan L, Macarie RD, Mihaila AC, Tucureanu MM, et al. Parathyroid Hormone Induces Human Valvular Endothelial Cells Dysfunction That Impacts the Osteogenic Phenotype of Valvular Interstitial Cells. *Int J Mol Sci*. 2022;23. doi: 10.3390/ijms23073776.
11. Lyle AN, Raaz U. Killing Me Unsoftly: Causes and Mechanisms of Arterial Stiffness. *Arterioscler Thromb Vasc Biol*. 2017;37:e1-e11. doi: 10.1161/atvbaha.116.308563.
12. Gambardella J, De Rosa M, Sorriento D, Prevete N, Fiordelisi A, Ciccarelli M, et al. Parathyroid Hormone Causes Endothelial Dysfunction by Inducing Mitochondrial ROS and Specific Oxidative Signal Transduction Modifications. *Oxid Med Cell Longev*. 2018;2018:9582319. doi: 10.1155/2018/9582319.
13. Jaminon A, Reesink K, Kroon A, Schurgers L. The Role of Vascular Smooth Muscle Cells in Arterial Remodeling: Focus on Calcification-Related Processes. *Int J Mol Sci*. 2019;20. doi: 10.3390/ijms20225694.
14. Nelson AJ, Raggi P, Wolf M, Gold AM, Chertow GM, Roe MT. Targeting Vascular Calcification in Chronic Kidney Disease. *JACC Basic Transl Sci*. 2020;5:398-412. doi: 10.1016/j.jacbs.2020.02.002.
15. Xia T, Yu J, Du M, Chen X, Wang C, Li R. Vascular endothelial cell injury: causes, molecular mechanisms, and treatments. *MedComm*. 2025;6:e70057.
16. Zhao Y, Su S, Li X. Parathyroid Hormone-Related Protein/Parathyroid Hormone Receptor 1 Signaling in Cancer and Metastasis. *Cancers (Basel)*. 2023;15. doi: 10.3390/cancers15071982.
17. Kashiwagi S, Morita A, Yokomizo S, Ogawa E, Komai E, Huang PL, et al. Photobiomodulation and nitric oxide signaling. *Nitric Oxide*. 2023;130:58-68. doi: 10.1016/j.niox.2022.11.005.
18. Penna C, Pagliaro P. Endothelial Dysfunction: Redox Imbalance, NLRP3 Inflammasome, and Inflammatory Responses in Cardiovascular Diseases. *Antioxidants (Basel)*. 2025;14:256. doi: 10.3390/antiox14030256.
19. Hu C-T, Shao Y-D, Liu Y-Z, Xiao X, Cheng Z-B, Qu S-L, et al. Oxidative stress in vascular calcification. *Clinica Chimica Acta*. 2021;519:101-10.
20. Leung SWS, Shi Y. The glycolytic process in endothelial cells and its implications. *Acta Pharmacol Sin*. 2022;43:251-9. doi: 10.1038/s41401-021-00647-y.
21. Wang S, Xu L, Wu Y, Shen H, Lin Z, Fang Y, et al. Parathyroid Hormone Promotes Human Umbilical Vein Endothelial Cell Migration and Proliferation Through Orai1-Mediated Calcium Signaling. *Front Cardiovasc Med*. 2022;9:844671. doi: 10.3389/fcvm.2022.844671.
22. Xie X, Yuan Y, Huang Y, Hong S, Chen G, et al. Effects of COL1A1 and SYTL2 on inflammatory cell infiltration and poor extracellular matrix remodeling of the vascular wall in thoracic aortic aneurysm. *Chinese Medical Journal*. 2024;137:1105-14.
23. Wu M, Zhang JD, Tang RN, Crowley SD, Liu H, Lv LL, et al. Elevated PTH induces endothelial-to-chondrogenic transition in aortic endothelial cells. *Am J Physiol Renal Physiol*. 2017;312:F436-f44. doi: 10.1152/ajprenal.00210.2016.
24. Cheng Z-Y, Ye T, Ling Q-Y, Wu T, Wu G-Y, Zong G-J. Parathyroid hormone promotes osteoblastic differentiation of endothelial cells via the extracellular signal-regulated protein kinase 1/2 and nuclear factor- κ B signaling pathways. *Exp Ther Med*. 2018;15:1754-60.
25. Dutta P, Lincoln J. Calcific Aortic Valve Disease: a Developmental Biology Perspective. *Curr Cardiol Rep*. 2018;20:21. doi: 10.1007/s11886-018-0968-9.